{"prompt": "['confirmed by a second assessment within approximately three weeks showing also a', 'significant decrease.', 'Heart failure and asymptomatic LVEF decline AEs must be graded per NCI CTCAE v4.0', '(see Appendix 7) and reported in the eCRF as described in Table 1.', '5.1.4.3.2', 'Hypersensitivity / Anaphylaxis and Administration-Related Reactions', '(Infusion or Injection)', 'Study treatment administration should be stopped in subjects who develop dyspnoea or', \"clinically significant hypotension (defined per investigator's discretion).\", 'Patients who experience any of the following events will be discontinued from study', 'treatment:', 'Grade 4 allergic reaction', 'Grade 3 or 4 hypersensitivity reaction', 'ARDS', 'Bronchospasm', 'Patients who experience ARRs may be managed by:', 'Slowing or stopping Perjeta IV or Herceptin IV infusion', 'Stopping the injection of pertuzumab and trastuzumab FDC SC', 'Supportive care with oxygen, -agonists, antihistamines, antipyretics, or corticosteroids', \"as appropriate at the investigator's discretion, as per institutional practice\", 'Subsequently pre-medicating with analgesia and antihistamines as per institutional', 'practice', 'Patients should be monitored until complete resolution of signs and symptoms of any', 'systemic reactions.', 'In order to be able to calculate time to onset of such reactions, the occurrence of associated', 'AEs must be documented with the date and time of the onset and duration of the event (i.e.,', 'resolution of the event).', 'All ARRs should be recorded as described in Section 5.2.4.3.', '5.1.4.3.3', 'EGFR-Related Toxicities', 'Diarrhoea', 'To prevent dehydration, early treatment of diarrhoea with anti-diarrheal medication (e.g.', 'loperamide) should be considered, and patients should be treated with fluids and electrolyte', 'replacement, as clinically indicated.', 'Rash / Skin Reactions', 'Treatment recommendations for EGFR-associated rash / skin reactions include topical or', 'oral antibiotics, topical pimecrolimus, and topical steroids or systemic steroids (for severe', 'reactions). These agents may be used in patients experiencing pertuzumab-related rash /', 'skin reactions, as clinically indicated, although they have not been studied in this context.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '65 / Protocol MO40628, Version 12']['Mucositis', 'Mucositis is generally not considered preventable. Although for some cytotoxic agents,', 'mucositis may be reduced by cooling the mouth using ice chips before and during the', 'infusion.', '5.2', 'SAFETY PARAMETERS AND DEFINITIONS', 'Safety assessments will consist of monitoring and recording AEs (including SAEs and AEs', 'of special interest), performing protocol-specified safety laboratory assessments, measuring', 'protocol-specified vital signs, and conducting other protocol-specified tests that are deemed', 'critical to the safety evaluation of the study.', 'Certain types of events require immediate reporting to the Sponsor, as outlined in Section', '5.4.', '5.2.1', 'Adverse Events', 'According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical', 'occurrence in a clinical investigation subject administered a pharmaceutical product,', 'regardless of causal attribution. An AE can therefore be any of the following:', 'Any unfavourable and unintended sign (including an abnormal laboratory finding),', 'symptom, or disease temporally associated with the use of a medicinal product, whether', 'or not considered related to the medicinal product', 'Any new disease or exacerbation of an existing disease (a worsening in the character,', 'frequency, or severity of a known condition) (see Sections 5.3.5.8 and 5.3.5.9 for more', 'information)', 'Recurrence of an intermittent medical condition (e.g., headache) not present at baseline', 'Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is', 'associated with symptoms or leads to a change in study treatment or concomitant', 'treatment or discontinuation from study drug', 'Adverse events that are related to a protocol-mandated intervention, including those that', 'occur prior to assignment of study treatment (e.g., screening invasive procedures such', 'as biopsies)', '5.2.2', 'Serious Adverse Events (Immediately Reportable to the Sponsor)', 'A serious adverse event is any AE that meets any of the following criteria:', 'Is fatal (i.e., the AE actually causes or leads to death)', 'Is life threatening (i.e., the AE, in the view of the investigator, places the patient at', 'immediate risk of death)', 'This does not include any AE that, had it occurred in a more severe form or was allowed', 'to continue, might have caused death.', 'Requires or prolongs inpatient hospitalization (see Section 5.3.5.10)', 'Results in persistent or significant disability / incapacity (i.e., the AE results in substantial', \"disruption of the patient's ability to conduct normal life functions)\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '66 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}